Abstract
The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-α based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
Keywords: Hepatitis C, insulin resistance, interferon-α, vascular disease, oxidative stress, Interferon (INF), interferon-receptor, Jak/STAT, ISGF3, HOMA-IR, SOCS3, protein phosphatase 2A, PIAS1, protein arginine methyl-transferase (PRMT1), B kinase-beta (IKK), Etanercept, TNF-protein, T1DM, T2DM, HEPATIC STEATOSIS (HS), metabolic steatosis, non alcoholic fatty liver disease, Thiazolidinediones, pioglitazone, rosiglitazone, peroxisome proliferator activated receptors, PPAR- mRNA, STATIN THERAPY AND CHC
Current Pharmaceutical Design
Title: Chronic Hepatitis C, Insulin Resistance and Vascular Disease
Volume: 16 Issue: 34
Author(s): Andreja Trpkovic, Edith Stokic, Djordje Radak, Zoran Gluvic, Mohamed Haidara, Dimitri P. Mikhailidis and Esma R. Isenovic
Affiliation:
Keywords: Hepatitis C, insulin resistance, interferon-α, vascular disease, oxidative stress, Interferon (INF), interferon-receptor, Jak/STAT, ISGF3, HOMA-IR, SOCS3, protein phosphatase 2A, PIAS1, protein arginine methyl-transferase (PRMT1), B kinase-beta (IKK), Etanercept, TNF-protein, T1DM, T2DM, HEPATIC STEATOSIS (HS), metabolic steatosis, non alcoholic fatty liver disease, Thiazolidinediones, pioglitazone, rosiglitazone, peroxisome proliferator activated receptors, PPAR- mRNA, STATIN THERAPY AND CHC
Abstract: The role of hepatitis C virus (HCV) infection in the development of vascular disease is controversial. Insulin resistance (IR) is a recognized risk factor for cardiovascular disease (CVD) and is associated with chronic hepatitis C (CHC). Thus, IR may promote atherosclerosis and vascular disease in CHC patients. HCV-associated IR may also cause hepatic steatosis and resistance to antiviral treatment. In addition, HCV may contribute a direct, proatherogenetic action on the vascular wall. This review considers the impact of IR on interferon-α based therapy of HCV infection and the role of insulin-sensitizing agents on the response to antiviral treatment and prevention of IR complications, including CVD.
Export Options
About this article
Cite this article as:
Trpkovic Andreja, Stokic Edith, Radak Djordje, Gluvic Zoran, Haidara Mohamed, P. Mikhailidis Dimitri and R. Isenovic Esma, Chronic Hepatitis C, Insulin Resistance and Vascular Disease, Current Pharmaceutical Design 2010; 16 (34) . https://dx.doi.org/10.2174/138161210794455067
DOI https://dx.doi.org/10.2174/138161210794455067 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma
Current Topics in Medicinal Chemistry Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Should Percutaneous Coronary Intervention be the Standard Treatment Strategy for Significant Coronary Artery Disease in all Octogenarians?
Current Cardiology Reviews From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Potential Cell Signalling Mechanisms Involved in Differential Placental Angiogenesis in Mild and Severe Pre-Eclampsia
Current Vascular Pharmacology bmp3 is Required for Integrity of Blood Brain Barrier by Promoting Pericyte Coverage in Zebrafish Embryos
Current Molecular Medicine Management of Hyperglycemia in Gestational Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Inflammation and Coronary Artery Disease
Current Vascular Pharmacology Patent Selections
Recent Patents on Cardiovascular Drug Discovery Can Exercise Minimize Postprandial Oxidative Stress in Patients with Type 2 Diabetes?
Current Diabetes Reviews Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets Diagnosis and Treatment of Dyslipidaemias in Athletes
Current Vascular Pharmacology Oxidative Stress in Cerebral Small Vessel Disease Dizziness Patients, Basally and After Polyphenol Compound Supplementation
Current Molecular Medicine Role of Bone-Type Tissue-Nonspecific Alkaline Phosphatase and PHOSPO1 in Vascular Calcification
Current Pharmaceutical Design The Post Hoc Use of Randomised Controlled Trials to Explore Drug Associated Cancer Outcomes: Methodological Challenges
Current Drug Safety The Impact of IL-17 in Atherosclerosis
Current Medicinal Chemistry Redox Sensitivity of Tyrosine Hydroxylase Activity and Expression in Dopaminergic Dysfunction
CNS & Neurological Disorders - Drug Targets Mediterranean Food Pattern in Rheumatoid Arthritis
Current Rheumatology Reviews Chloride Channels − New Targets for the Prevention of Stroke
Current Vascular Pharmacology